Millennium Outbids Genzyme to Acquire AnorMED for $515 Million
ePT--the Electronic Newsletter of Pharmaceutical Technology
Millennium Pharmaceuticals, Inc. entered into an agreement to acquire biopharmaceutical company AnorMED, Inc. (Langley, BC, Canada) for $515 million.
Cambridge, MA (Sept. 26)-Millennium Pharmaceuticals, Inc. (www.mlnm.com) entered into an agreement to acquire biopharmaceutical company AnorMED, Inc. (Langley, BC, Canada, www.anormed.com) for $515 million. Millennium will acquire all AnorMED’s outstanding common shares for US$12.00 per share in cash. The total purchase is 40% more than Genzyme Corporation’s (Cambridge, MA, www.genzyme.com) unsolicited tender offer ($8.55 cash per share) on Sept. 1, 2006.
The deal will give Millennuim access to AnorMED’s “Mozobil” lead hematology-oncology product, which is in late-stage Phase III trials in cancer patients undergoing stem cell transplants. The company expects the product to be on the market in 2008.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
